We don’t know for sure,” said Dr. John Evans, chair of the board of directors at MARS (Medical and Related Sciences) Discovery District in Toronto, and vicechair of Mississauga, Ont.-based NPSAllelix Biopharmaceuticals, one of the pioneers of biotech in Canada. “But we believe that if you could ‘type’ the patient processes of how he/she handles a drug, you could peel off those people who would be particularly sensitive to a drug. Then you could find a sub-population where the drug is safe and highly effective.” Evans used the arthritis drug Vioxx as an example. It helped millions of people battle painful inflammation, but was pulled from the market recently because of potential cardiac side effects in some people. “If the drug company could have predicted which patients would have complications from Vioxx treatment — through some genetic profiling — then a very powerful and effective drug could have been preserved,” Evans said. His company, NPS-Allelix Bio-pharmaceuticals, has been developing a product since 1989 that will be launched later this year. The drug secretes a parathyroid hormone for treating osteoporosis.

It builds up bone matrix and helps build bone, rather than just delay bone loss as other drugs do.

Three technology research centres in Ontario Monday said they have agreed to work together to help the province compete more effectively against countries like India and China.

Communitech is working with the Ottawa Centre for Research and Innovation, an economic development corporation located in the nation's capital, and the MaRS Discovery District, a Toronto-based not-for-profit geared towards the commercialization of scientific and technological intellectual property.

MaRS originally stood for Medical and Research Sciences, but has since shied away from that label, said Ross Wallace, director of corporate strategy. The organization doesn't want to be pigeonholed as being just a life sciences or biotechnology outfit -- it lends equal weight to information communications and advanced manufacturing. MaRS may be Toronto-based, but its mandate is province-wide, said Wallace. By joining forces with organizations in other parts of Ontario, MaRS is more likely to fulfill that mandate, he said.

Groups like MaRS and OCE exist to offer funding and managerial guidance to help entrepreneurs take their great con- cept to market. Our role at MaRS is to help innovators bridge this commercialization gap. We provide advisory services, market intelligence and seed funding in conjunc-

tion with OCE

Veronika Litinski is the Director of MaRS Venture Group. For assistance in drafting this article, thanks to Kevin Downing, Asso- ciate with MaRS Venture Group

In November, Skymeter moved into the incubator at the MaRS Centre, where marketing expert Peter Evans has become their mentor and godfather. "Being surrounded by other entrepreneurs is inspiring and enlightening," Hassan says. "MaRS is an amazing place, with excellent speakers and events that are open to the public."

The father of Skymeter Corp. – which developed a BlackBerry-sized device that uses GPS signals; placed in vehicles, it meters the use of roads, parking and pay-as-you-drive insurance

Skymeter's black box will be attached to the windshield of cars so the box has a clear view of the sky. (Grush has figured out how to cope with tall buildings blocking signals.) The box contains a GPS receiver, some memory, a processor and a telecommunications chip. The satellite beams down to the earth, the GPS receiver computes where it is and uploads its history to a data centre to generate the bill. The vehicle measures its own use; the bill is itemized like a cellphone bill. If you prepay, the bill can be calculated on board.